During tumor progression in breast, prostate, gastric, and pancreatic cancers [36], [37], the development of a mesenchymal phenotype and the loss of E-cadherin expression are often associated with the expression of mesenchymal cadherins such as N-cadherin and/or Cad11. Here, CDH2 is linked to neoplasm.